Author Credentials

Jacob Randal Kilgore, MD Joan C. Edwards School of Medicine at Marshall University kilgore30@marshall.edu James Clayton Curry, MS4 Joan C. Edwards School of Medicine at Marshall University Curry162@marshall.edu Shane E. Cook, MD Boone Memorial Hospital Drcook.se@gmail.com

Author ORCID Identifier



psoriasis, Guselkumab, Tremfya, Lentigines


Dermatology | Medicine and Health Sciences | Other Pharmacy and Pharmaceutical Sciences


Eruptive lentigines in the area of resolving psoriatic plaques has been well documented in the literature following successful treatment with multiple therapies. This is historically associated with light treatment but has been expanded to include other therapies such as anti-tumor necrosis factor therapies and, more recently, some biologics5. Guselkumab (Tremfya) is an IgG1λ monoclonal antibody used in the treatment of plaque psoriasis with only one case of eruptive lentigines confined to resolving psoriatic plaques (ELRP) noted as a side effect. We present the second such case of ELRP associated with successful treatment of plaque psoriasis with Guselkumab, as it is important to document potential side effects of medications regardless of their severity.